Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GB-4362 Administered With Enfortumab Vedotin and Pembrolizumab in Participants With Advanced Urothelial Cancer

NCT07484022 is registered in ClinicalTrials.gov with Generate Biomedicines as lead sponsor.

NCT NCT07484022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07484022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GB-4362 Administered With Enfortumab Vedotin and Pembrolizumab in Participants With Advanced Urothelial Cancer
Lead sponsor
Generate Biomedicines
Phase
Phase 1
Overall status
Recruiting
Start date
June 8, 2026
Completion date
December 31, 2027
Enrollment
37 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced urothelial cancer, metastatic urothelial carcinoma